Results
We found no differences between W
and B children by transplant characteristics, other than donor type.
There was a significant difference in use of HLA-mismatched donors
(HLA-MMD) (53% W, 71% B, p =0.01). When comparing HLA-MMD use to
fully HLA-matched donors, B had RR of 1.47 [95% CI 0.7-3] of
receiving a mismatched unrelated donor (MMUD), RR of 2.34 [95% CI
1.2-4.4] of receiving a mismatched related donor (MMRD), and a RR of
1.9 [95% CI 0.99-3.6] of receiving a mismatched cord blood donor
(MMCBD) HCT, respectively. There was no significant difference in the
incidence of aGVHD (48% W, 35% B), p=0.1 or cGVHD (19% W 28% B,p =0.1), or primary cause of death. Overall 24-month survival was
61% [95% CI 54-68%] for W, and 60% [95% CI 38-68] for B
children, log-rank p=0.72. While HLA matching improved survival in W
children, the number of B children receiving HLA-matched HCT was too
small to identify the impact of HLA matching on survival.